Assenagon Asset Management S.A. Buys 14,756 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

Assenagon Asset Management S.A. lifted its position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 13.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,008 shares of the company's stock after purchasing an additional 14,756 shares during the quarter. Assenagon Asset Management S.A. owned 0.65% of USANA Health Sciences worth $4,702,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of USNA. BOKF NA raised its stake in USANA Health Sciences by 274.5% during the first quarter. BOKF NA now owns 2,771 shares of the company's stock worth $133,000 after acquiring an additional 2,031 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company's stock worth $284,000 after acquiring an additional 494 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in USANA Health Sciences by 4.4% during the third quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company's stock worth $292,000 after acquiring an additional 322 shares in the last quarter. SG Americas Securities LLC acquired a new position in USANA Health Sciences during the second quarter worth $340,000. Finally, Creative Planning acquired a new position in USANA Health Sciences during the third quarter worth $394,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Price Performance

Shares of USNA stock traded down $0.51 during trading hours on Wednesday, hitting $36.79. 64,006 shares of the company's stock were exchanged, compared to its average volume of 80,894. The stock's 50-day moving average is $37.81 and its 200-day moving average is $42.29. The stock has a market cap of $700.92 million, a price-to-earnings ratio of 12.98, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. USANA Health Sciences, Inc. has a 52 week low of $34.15 and a 52 week high of $54.81.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.49 by $0.07. The company had revenue of $200.22 million for the quarter, compared to analysts' expectations of $208.45 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same quarter in the prior year, the business earned $0.59 earnings per share. Equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 674 shares of the firm's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Gilbert A. Fuller sold 674 shares of the firm's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Paul A. Jones sold 6,266 shares of the firm's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Company insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. DA Davidson dropped their price objective on USANA Health Sciences from $38.00 to $35.00 and set a "neutral" rating for the company in a research note on Wednesday, October 23rd. StockNews.com lowered USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, July 24th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.